This is because, in addition to conversion of angiotensin I to angiotensin II, ACE also inactivates bradykinin and substance P. Notably, a recent gene expression analysis by Garvin and colleagues has documented downregulation of ACE (Speth, 2020) in COVID‐19 patients (Garvin et al., 2020) suggesting that not only bradykinin but also the levels of substance P could be elevated. This evidence concerns the gene TAC1 and COVID-19.